Table 1 Demographics and medications for JDM patients and healthy controls
From: Serum protein biomarkers for juvenile dermatomyositis: a pilot study
JDMa | Controls (SomaScan®) | Controls (ELISA) | |||
|---|---|---|---|---|---|
Baselinen = 8 | On Treatmentn = 7 | Inactiven = 8b | n = 12 | n = 17 | |
Age, yr, mean (stdv) | 6.8 (2.7) | 7.8 (2.7) | 9.3 (1.9) | 8.5 (1.7) | 8.3 (2.3) |
Gender | |||||
Female, n | 8 | 7 | 8 | 0 | 17 |
Male, n | 0 | 0 | 0 | 12 | 0 |
DAS Total,c mean (stdv) | 11.0 (3.5) | 4.6 (5.3) | 0.6 (0.9) | ||
DAS Skin,c mean (stdv) | 5.6 (1.7) | 1.9 (2.0) | 0.3 (0.5) | ||
DAS Muscle,c mean (stdv) | 5.4 (3.3) | 2.8 (3.4) | 0.3 (0.6) | ||
Months between samples,mean (stdv) | 7.4 (3.6) | 20.8 (11.1) | |||
Drug, x = total patients on drug during studyd | Months on drug at sample mean (stdv)n = x | ||||
IV solumedrol, n = 7 | n = 0 | 3.8 (1.0), n = 3 | n = 0 | ||
oral prednisone, n = 8 | n = 0 | 6.6 (3.6), n = 7 | 20.8 (11.0), n = 3 | ||
methotrexate, n = 7 | n = 0 | 7.5 (3.9), n = 5 | 17.7 (0.9), n = 2 | ||
cyclosporine, n = 2 | n = 0 | 1.9, n = 1 | n = 0 | ||
mycophenolate mofetil, n = 5 | n = 0 | 3.7 (3.1), n = 3 | 7.4 (6.8), n = 2 | ||
hydroxychloroquine, n = 2 | n = 0 | 4.9 (4.9), n = 2 | 27.2 (16.0), n = 2 | ||